Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,582 shares of the company's stock after selling 12,637 shares during the quarter. Van ECK Associates Corp owned 0.08% of Neurocrine Biosciences worth $9,618,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. 1832 Asset Management L.P. lifted its position in shares of Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock worth $74,507,000 after purchasing an additional 504,400 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock worth $166,959,000 after acquiring an additional 228,444 shares during the last quarter. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company's stock worth $1,369,673,000 after acquiring an additional 220,598 shares during the period. Iron Triangle Partners LP acquired a new position in Neurocrine Biosciences during the 1st quarter valued at $30,342,000. Finally, Renaissance Technologies LLC boosted its holdings in Neurocrine Biosciences by 9.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock valued at $339,790,000 after purchasing an additional 216,500 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares of the company's stock, valued at approximately $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the company's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total value of $2,120,358.00. Following the sale, the chief financial officer now owns 31,528 shares of the company's stock, valued at $4,741,180.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,063 shares of company stock worth $7,023,330 in the last three months. 4.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on NBIX. Citigroup upped their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a research note on Friday, August 2nd. Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a research note on Tuesday, October 29th. BMO Capital Markets cut their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research note on Thursday, October 17th. Robert W. Baird upped their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Finally, Raymond James reiterated an "outperform" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Stock Down 0.8 %

NASDAQ:NBIX traded down $0.95 during mid-day trading on Thursday, hitting $124.35. 361,807 shares of the company traded hands, compared to its average volume of 863,250. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98. The firm has a market cap of $12.59 billion, a price-to-earnings ratio of 33.59 and a beta of 0.35. The stock's fifty day moving average price is $118.54 and its 200-day moving average price is $133.28.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.